

Xilloc raises growth finance from Holland Capital

Geleen/Amsterdam, July 2nd 2021 - Xilloc, a leading innovator and producer of medical implants and devices, has raised growth finance for its international expansion and product development from Holland Capital.

Xilloc is specialized in the design, production and supply of patient-specific implants, such as Cranio-Maxillofacial implants, and a unique implant for people with lower extremity amputations.

Click Safety Adapter

Osseointegration is a technique where a titanium implant is placed in the bones of the upper and or lower leg. Xilloc developed an innovative, patent-protected Nexus Click Safety Adapter, a product used to safely connect a prosthetic leg onto an osseointegrated implant. Through this connection the prosthetic leg forms a stable unity with the skeleton. This provides multiple benefits compared to a socket connection and therefore improves the quality of life.

International ambitions

The collaboration with Holland Capital will support the international product commercialization of Xilloc. Xilloc has the ambition to become the market leader in the field of osseointegration for lower extremities.

"The investment of Holland Capital reflects a strong trust in Xilloc's unique product portfolio. In addition, they make it possible to expand our existing portfolio with more innovative products," says Maikel Beerens, Founder/CTIO Xilloc.

Milko Wijckmans, CEO of Xilloc, comments: *"Holland Capital further supports our growth ambitions. They will add value to Xilloc through their experience, expertise and network. As a team, we are looking forward to working with Holland Capital."*

Jan Frens van Giessel, partner Holland Capital: *"Xilloc has built a strong product portfolio in recent years and has uniquely positioned itself into the market. With this investment, we want to support further international commercialization. I am looking forward to working with the team to make Xilloc a success."*

Over Xilloc

Xilloc was founded in 2011 by Maikel Beerens as a spin-off from Maastricht UMC+. The company made the world's first 3D printed full titanium mandibular implant. In recent years, Xilloc built an extensive product portfolio and has together with its customers successfully helped more than 3000 patients worldwide.

www.xilloc.com

Over Holland Capital

Over the past 40 years, Holland Capital has responsibly and successfully invested in over more than 140 SME-companies. With a clear investment strategy Holland Capital is active in the attractive growth markets of Healthcare and Technology. Holland Capital's experienced and committed investment team aims to establish an open, sustainable and professional relationship with the companies they invest in, with the common goal of achieving growth. Holland Capital is backed by a broad network of successful healthcare entrepreneurs in the relevant growth markets. www.hollandcapital.nl

Note for press, not for publication

Holland Capital, Grytsje de Jong (marketing manager), grytsje.dejong@hollandcapital.nl